logo
Sign in

AIM Stock Price, Chart, Stats & News

AIM ImmunoTech Inc.
Save

AIM ImmunoTech Inc. (AIM) does not currently pay a dividend.

847,481
Market cap
Current P/E
2.01x
Forward P/E

AIM chart

1M
3M
1Y
5Y
Loading chart...

About

AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.

Similar securities

Based on sector and market capitalization

Report issue